Bone metastasis: Histological changes and pathophysiological mechanisms in osteolytic or osteosclerotic localizations. A review

Morphologie

Volumn 95, Issue 309, 2011, Pages 65-75

  Chappard, D ^a   Bouvard, B ^a   Basle M F ^a   Legrand, E ^a   Audran, M ^a  

^a ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

Bone malignancy; Bone metastasis; Osteolysis; Osteosclerosis; Pathophysiology

Indexed keywords

CYTOKINE; ENDOTHELIN 1; GROWTH FACTOR; INTERLEUKIN 1; INTERLEUKIN 6; PARATHYROID HORMONE RELATED PROTEIN; SOMATOMEDIN;

BONE CELL; BONE MARROW; BONE METASTASIS; CANCER CELL; HISTOPATHOLOGY; HUMAN; NONHUMAN; OSTEOLYSIS; OSTEOSCLEROSIS; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

EID: 80955180997     PISSN: 12860115     EISSN: 12860115     Source Type: Journal    
DOI: 10.1016/j.morpho.2011.02.004     Document Type: Short Survey

References (56)

1. Guise T.A., Mundy G.R. Cancer and bone. Endocr Rev 1998, 19:18-54.
2. Calvi L.M., Adams G.B., Weibrecht K.W., Weber J.M., Olson D.P., Knight M.C., et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003, 425:841-846.
3. Boyle W.J., Simonet W.S., Lacey D.L. Osteoclast differentiation and activation. Nature 2003, 423:337-342.
4. Frost H.M. The pathomechanics of osteoporoses. Clin Orthop Relat Res 1985, 198-225.
5. Frost H.M. Some ABCs of skeletal pathophysiology III: Bone balance and the delta B. BMU. Calcif Tissue Int 1989, 45:131-133.
6. Bonewald L.F., Mundy G.R. Role of transforming growth factor-beta in bone remodeling. Clin Orthop Relat Res 1990, 261-276.
7. Erlebacher A., Filvaroff E.H., Ye J.Q., Derynck R. Osteoblastic responses to TGF-beta during bone remodeling. Mol Biol Cell 1998, 9:1903-1918.
8. Libouban H., Filmon R., Maureac A., Basle M.F., Chappard D. Fetuin and osteocalcin interact with calcospherite formation during the calcification process of poly (2-hydroxyethylmethacrylate) in vitro: a Raman microspectroscopic monitoring. J Raman Spectrosc 2009, 40:1234-1239.
9. Eghbali-Fatourechi G., Khosla S., Sanyal A., Boyle W.J., Lacey D.L., Riggs B.L. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 2003, 111:1221-1230.
10. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., et al. a novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319.
11. Matsuo K., Irie N. Osteoclast-osteoblast communication. Arch Biochem Biophys 2008, 473:201-209.
12. Lee S.H., Rho J., Jeong D., Sul J.Y., Kim T., Kim N., et al. v-ATPase V0 subunit d2-deficient mice exhibit impaired osteoclast fusion and increased bone formation. Nat Med 2006, 12:1403-1409.
13. Stoker M., Perryman M. An epithelial scatter factor released by embryo fibroblasts. J Cell Sci 1985, 77:209-223.
14. Ansieau S., Hinkal G., Morel A.P., Puisieux A. Revisiting the canonical tumour progression model. Pathol Biol (Paris) 2011, online. 10.1016/j.patbio.2009.11.005.
15. Liao D., Johnson R.S. Hypoxia: A key regulator of angiogenesis in cancer. Cancer Metast Rev 2007, 26:281-290.
16. Semenza G.L. Angiogenesis in ischemic and neoplastic disorders. Annu Rev Med 2003, 54:17-28.
17. Pugsley M.K., Tabrizchi R. The vascular system: An overview of structure and function. J Pharmacol Toxicol Methods 2000, 44:333-340.
18. Fidler I.J. The pathogenesis of cancer metastasis: the seed and soil' hypothesis revisited. Nat Rev Cancer 2003, 3:453-458.
19. Blouin S., Baslé M.F., Chappard D. Interactions between microenvironment and cancer cells in two animal models of bone metastasis. Br J Cancer 2008, 98:809-815.
20. Chappard D., Libouban H., Legrand E., Ifrah N., Masson C., Baslé M.F. Computed microtomography of bone specimens for rapid analysis of bone changes associated with malignancy. Anat Rec 2010, 293:1125-1133.
21. Blouin S., Baslé M.F., Chappard D. Rat models of bone metastases. Clin Exp Metastasis 2005, 22:605-614.
22. Hiscox S., Morgan L., Green T.P., Barrow D., Gee J., Nicholson R.I. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res Treat 2006, 97:263-274.
23. Leinung S., Wurl P., Schonfelder A., Weiss C.L., Roder I., Schonfelder M. Detection of cytokeratin-positive cells in bone marrow in breast cancer and colorectal carcinoma in comparison with other factors of prognosis. J Hematother Stem Cell Res 2000, 9:905-911.
24. Powell G.J., Southby J., Danks J.A., Stillwell R.G., Hayman J.A., Henderson M.A., et al. Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites. Cancer Res 1991, 51:3059-3061.
25. Blouin S., Moreau M.F., Baslé M.F., Chappard D. Relations between radiograph texture analysis and microcomputed tomography in two rat models of bone metastases. Cells Tissues Organs 2006, 182:182-192.
26. Guise T.A. Molecular mechanisms of osteolytic bone metastases. Cancer 2000, 88:2892-2898.
27. Boucharaba A., Serre C.M., Gres S., Saulnier-Blache J.S., Bordet J.C., Guglielmi J., et al. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest 2004, 114:1714-1725.
28. Guise T.A., Chirgwin J.M. Transforming growth factor-beta in osteolytic breast cancer bone metastases. Clin Orthop Relat Res 2003, 415S:32-38.
29. Chappard D., Laurent J.L., Bousquet G., Riffat G., Odelin M.F. Mean osteoplastic surface in zones of plexiform neo-osteogenesis compared with mean osteoplastic surface measured on the fetal bone. Bull Assoc Anat (Nancy) 1978, 62:389-399.
30. Wlodarski K.H., Reddi H.A. Tumor cells stimulate in vivo periosteal bone formation. Bone Miner 1987, 2:185-192.
31. Coleman R.E. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006, 12:S6243-6249.
32. Nelson W.G., De Marzo A.M., Isaacs W.B. Prostate cancer. N Engl J Med 2003, 349:366-381.
33. Chinni S.R., Yamamoto H., Dong Z., Sabbota A., Bonfil R.D., Cher M.L. CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone. Mol Cancer Res 2008, 6:446-457.
34. Hu W., Zhen X., Xiong B., Wang B., Zhang W., Zhou W. CXCR6 is expressed in human prostate cancer in vivo and is involved in the in vitro invasion of PC3 and LNCap cells. Cancer Sci 2008, 99:1362-1369.
35. Shiozawa Y., Havens A.M., Jung Y., Ziegler A.M., Pedersen E.A., Wang J., et al. Annexin II/annexin II receptor axis regulates adhesion, migration, homing, and growth of prostate cancer. J Cell Biochem 2008, 105:370-380.
36. Granchi S., Brocchi S., Bonaccorsi L., Baldi E., Vinci M.C., Forti G., et al. Endothelin-1 production by prostate cancer cell lines is up-regulated by factors involved in cancer progression and down-regulated by androgens. Prostate 2001, 49:267-277.
37. Takuwa Y., Masaki T., Yamashita K. The effects of the endothelin family peptides on cultured osteoblastic cells from rat calvariae. Biochem Biophys Res Commun 1990, 170:998-1005.
38. Chiao J.W., Moonga B.S., Yang Y.M., Kancherla R., Mittelman A., Wu-Wong J.R., et al. Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption. Br J Cancer 2000, 83:360-365.
39. Lu Y., Zhang J., Dai J., Dehne L.A., Mizokami A., Yao Z., et al. Osteoblasts induce prostate cancer proliferation and PSA expression through interleukin-6-mediated activation of the androgen receptor. Clin Exp Metastasis 2004, 21:399-408.
40. Nakashima J., Tachibana M., Horiguchi Y., Oya M., Ohigashi T., Asakura H., et al. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 2000, 6:2702-2706.
41. Shariat S.F., Andrews B., Kattan M.W., Kim J., Wheeler T.M., Slawin K.M. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology 2001, 58:1008-1015.
42. Deftos L.J., Barken I., Burton D.W., Hoffman R.M., Geller J. Direct evidence that PTHrP expression promotes prostate cancer progression in bone. Biochem Biophys Res Commun 2005, 327:468-472.
43. Libouban H., Moreau M.F., Baslé M.-F., Bataille R., Chappard D. Increased bone remodeling due to ovariectomy dramatically increases tumoral growth in the 5T2 multiple myeloma mouse model. Bone 2003, 33:283-292.
44. Padalecki S.S., Guise T.A. Actions of bisphosphonates in animal models of breast cancer. Breast Cancer Res 2002, 4:35-41.
45. Libouban H., Le Drévo M.A., Moreau M.F., Baslé M.F., Chappard D. Dietary calcium deficiency increases osteolysis and modifies gene expression profile in an animal model of multiple myeloma. Calcif Tissue Int 2008, 82:S35. [abstract].
46. Zheng Y., Zhou H., Modzelewski J.R., Kalak R., Blair J.M., Seibel M.J., et al. Accelerated bone resorption, due to dietary calcium deficiency, promotes breast cancer tumor growth in bone. Cancer Res 2007, 67:9542-9548.
47. Russell R.G., Rogers M.J. Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999, 25:97-106.
48. Dunford J.E., Rogers M.J., Ebetino F.H., Phipps R.J., Coxon F.P. Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac Cdc42, and Rho GTPases. J Bone Miner Res 2006, 21:684-694.
49. Green J.R., Clezardin P. Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis. Am J Clin Oncol 2002, 25:S3-9.
50. Costa L. Bisphosphonates: reducing the risk of skeletal complications from bone metastasis. Breast 2007, 16S3:16-20.
51. Green J.R. Skeletal complications of prostate cancer: pathophysiology and therapeutic potential of bisphosphonates. Acta Oncol 2005, 44:282-292.
52. Nyangoga H., Blouin S., Libouban H., Baslé M.F., Chappard D. A single pretreatment by zoledronic acid converts metastases from osteolytic to osteoblastic in the rat. Microsc Res Tech 2010, 8:733-740.
53. Marx R.E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003, 61:1115-1117.
54. Neville-Webbe H.L., Coleman R.E. Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease. Eur J Cancer 2010, 46:1211-1222.
55. Idris A.I., Libouban H., Nyangoga H., Landao-Bassonga E., Chappard D., Ralston S.H. Pharmacologic inhibitors of IkappaB kinase suppress growth and migration of mammary carcinosarcoma cells in vitro and prevent osteolytic bone metastasis in vivo. Mol Cancer Ther 2009, 8:2339-2347.
56. Badraoui R., Blouin S., Moreau M.F., Gallois Y., Rebai T., Sahnoun Z., et al. Effect of alpha tocopherol acetate in Walker 256/B cells-induced oxidative damage in a rat model of breast cancer skeletal metastases. Chem Biol Interact 2009, 182:98-105.